SCHEMBL3471383

SCHEMBL3471383

FC(F)(F)c1cc(-c2cc(Br)cs2)n(-c2ccccc2N2CCOCC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.40
KDM4E B2RXH2 2/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPSR1 Q6W5P4 3/20 0.39
HTT P42858 1/20 0.39
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RXRA P19793 2/20 0.37
NR1H2 P55055 2/20 0.37
NR1H3 Q13133 2/20 0.37
AR P10275 2/20 0.37
PTGS1 P23219 2/20 0.36
SYK P43405 1/20 0.35
ALDH1A1 P00352 2/20 0.34
LMNA P02545 2/20 0.34
KMT2A Q03164 1/20 0.34
PTGS2 P35354 1/20 0.34
S1PR1 P21453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3471413 0.80 RXRA (0.56) RXRANR1H2NR1H3ARPTGS1
SCHEMBL14622714 0.80 RXRA (0.41) RXRANR1H2NR1H3PTGS1PTGS2
SCHEMBL3477572 0.80 RXRA (0.54) RXRANR1H2NR1H3PTGS1PTGS2
SCHEMBL3473039 0.77 PTGS2 (0.43) RXRANR1H2NR1H3PTGS1PTGS2
SCHEMBL8689110 0.75 PTGS2 (0.48) RXRANR1H2NR1H3PTGS1PTGS2
SCHEMBL3471683 0.69 RXRA (0.57) RXRANR1H2NR1H3PTGS1PTGS2
SCHEMBL3471275 0.68 RXRA (0.48) RXRANR1H2NR1H3PTGS1PTGS2
SCHEMBL3471163 0.68 RXRA (0.56) KDM4ENPSR1RXRANR1H2NR1H3
SCHEMBL3475254 0.67 RXRA (0.47) RXRANR1H2NR1H3PTGS1PTGS2
SCHEMBL14732136 0.67 PTGS2 (0.72) TSHRPTGS1LMNAPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 TDP1 3914/4885KDM4E 1934/4885TSHR 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.